• Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair. Both combinations of aclidinium/formoterol showed statistically significant improvements in the co-primary endpoints of change from baseline in morning predose through FEV1 vs. formoterol and in FEV1 at one-hour post-dose vs. aclidinium (p < 0.01 and p = 0.0001 , respectively). Also, both combinations of aclidinium/formoterol provided statistically significant improvements vs. placebo in those two variables (both p < 0.0001). The combination product is in development for chronic obstructive pulmonary disorder.

• Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like peptide 1 receptor agonist, to insulin glargine, as measured by the reduction of hemoglobin A1c levels, were met in two studies, AWARD-2 and AWARD-4. Dulaglutide is being studied as a once-weekly treatment for Type II diabetes.